A team of Canadian researchers from the University of Waterloo has determined precisely how the female hormone estrogen mitigates the risks associated with high blood pressure. It was discovered that its principal function lies in its capacity to relax and widen blood vessels. This research was featured in the journal Mathematical Biosciences (MB).
Hypertension affects over a billion people globally, remaining a leading contributor to cardiovascular diseases and strokes. Both scientists and practicing physicians have long noted that women pre-menopause experience hypertension less frequently than men or women post-menopause.
Experts suspected this effect was linked to estrogen’s influence, yet the exact mechanism of its protective action remained unclear for a significant period. To elucidate the matter, the investigators employed a mathematical model that describes the operational logic of the cardiovascular system and the kidneys. This model allows for the separate tracking of distinct biological effects and an assessment of how each one impacts pressure levels.
The study’s authors clarify that estrogen influences numerous bodily processes, ranging from the condition of the blood vessels to how the kidneys regulate fluid levels. However, the simulation confirmed that the hormone’s ability to induce vasodilation—the widening of vessels—is the decisive element.
When blood vessels dilate, blood flow is eased, which helps maintain optimal arterial pressure. This proves to be a crucial factor in shielding women from hypertension before menopause.
The model developed by the researchers grants experts the ability to test diverse scenarios, which is markedly difficult to achieve in human-based experiments.
The simulation also aided in comparing the efficacy of various medications used to treat hypertension. It was found that for women, angiotensin receptor blockers, designed to prevent vessel constriction, might be more effective. According to the scientists’ calculations, these could perform better than angiotensin-converting enzyme inhibitors, even in the post-menopausal period.
Such models, the scientists believe, will facilitate the creation of personalized strategies for managing cardiovascular ailments.
About the Author
